News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Vonage Communications APIs allow developers to easily enhance and build intelligent, intuitive customer experiences directly into their existing applications and devices
It is being developed by Pune-based Gennova Biopharmaceuticals
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
Subscribe To Our Newsletter & Stay Updated
